| Formulary Chapter 3: Respiratory system - Full Section
|
Notes:
Prescribing inhalers
• Prescribe by brand or branded-generic name to ensure patients receive the device they are used to.
• Check licensed indication (differences among brands).
• Be aware of differences in excipients among the different brands. |
| Useful Links |
 COPD Guidelines 2017- Pan Birmingham Respiratory Clinical Network |
|
Equality Analysis - Diagnosis and management of stable COPD- Pan Birmingham Respiratory Clinical Network guideline 2017 |
|
Appendix 4 Criteria for triple therapy and for triple inhaler use in COPD |
|
NICE TA10: Asthma inhaler devices (children under 5) |
|
UKMI Q&A: Nebuliser compatibilities |
|
Diagnosis and Management of Asthma in Adults Guideline - Pan Birmingham Respiratory Clinical Network (June 2019) |
|
NICE CG101: COPD guideline |
|
NICE TA38: Asthma inhaler devices (older children) |
|
Stoma Toolkit Adults |
| Numbers in brackets indicate counts of (Formulary items, Non Formulary items)
|
|
03.01 |
Bronchodilators (0,0)
|
|
|
Asthma (0,0)
|
|
|
Chronic obstructive pulmonary disease (0,0)
|
|
|
Croup (0,0)
|
|
03.01.01 |
Adrenoceptor agonists (0,0)
|
|
03.01.01.01 |
Selective Beta2 agonists
(7,4)
|
|
|
Short-acting beta2 agonists (0,0)
|
|
|
Long-acting beta2 agonists (0,0)
|
|
03.01.01.02 |
Other adrenoceptor agonists
(0,2)
|
|
03.01.02 |
Antimuscarinic bronchodilators
(5,1)
|
|
|
Short Acting Anti-muscarinic Bronchodilators (0,0)
|
|
|
Long Acting Anti-muscarinic Bronchodilators (0,0)
|
|
03.01.03 |
Theophylline
(3,2)
|
|
03.01.04 |
Compound bronchodilator preparations
(4,2)
|
|
03.01.05 |
Peak flow meters, inhaler devices and nebulisers
(0,1)
|
|
|
Peak flow meters
(2,0)
|
|
|
Drug delivery devices
(2,0)
|
|
|
Nebuliser Diluent
(1,0)
|
|
03.02 |
Corticosteroids
(12,8)
|
|
03.02.01 |
Inhaled Corticosteroids (0,0)
|
|
03.02.02 |
Combination products (ICS+LABA) for asthma (0,0)
|
|
|
Low dose (0,0)
|
|
|
Moderate dose (0,0)
|
|
|
High dose (0,0)
|
|
03.02.03 |
Combination products (ICS+LABA) for COPD
(2,0)
|
|
03.03 |
Cromoglicate, related therapy and leukotriene receptor antagonists (0,0)
|
|
03.03.01 |
Cromoglicate and related therapy
(0,4)
|
|
|
Related therapy (0,0)
|
|
03.03.02 |
Leukotriene receptor antagonists
(1,1)
|
|
03.03.03 |
Phosphodiesterase type-4 inhibitors
(1,0)
|
|
03.04 |
Antihistamines, hyposensitisation, and allergic emergencies (0,0)
|
|
03.04.01 |
Antihistamines (0,0)
|
|
|
Non-sedating antihistamines
(3,6)
|
|
|
Sedating antihistamines
(4,3)
|
|
03.04.02 |
Allergen Immunotherapy
(4,0)
|
|
|
Omalizumab (0,0)
|
|
03.04.03 |
Allergic emergencies (0,0)
|
|
|
Anaphylaxis
(3,2)
|
|
|
Angioedema
(5,0)
|
|
|
Intramuscular adrenaline (epinephrine) (0,0)
|
|
|
Intravenous adrenaline (epinephrine)
(0,1)
|
|
|
Self-administration of adrenaline (epinephrine) (0,0)
|
|
03.05 |
Respiratory stimulants and pulmonary surfactants (0,0)
|
|
03.05.01 |
Respiratory stimulants
(2,0)
|
|
03.05.02 |
Pulmonary surfactants
(1,1)
|
|
03.06 |
Oxygen
(1,0)
|
|
|
Long-term oxygen therapy (0,0)
|
|
|
Short burst oxygen therpary (0,0)
|
|
|
Ambulatory oxygen therapy (0,0)
|
|
|
Oxygen therapy equipment (0,0)
|
|
|
Arrangements for supplying oxygen (0,0)
|
|
03.07 |
Mucolytics
(6,1)
|
|
|
Dornase alfa
(1,0)
|
|
|
Hypertonic Sodium Chloride
(2,3)
|
|
03.08 |
Aromatic inhalations
(0,3)
|
|
03.09 |
Cough preparations (0,0)
|
|
03.09.01 |
Cough suppressants
(1,6)
|
|
|
Palliative care
(1,1)
|
|
03.09.02 |
Expectorant and demulcent cough preparations
(2,1)
|
|
03.10 |
Systemic nasal decongestants
(1,0)
|
|
03.11 |
Antifibrotics
(2,0)
|
|
03.12 |
Other drugs for Interstitial lung disease (idiopathic pulmonary fibrosis)
(3,0)
|
|
03.13 |
Nebulised antibiotics for cystic fibrosis
(8,0)
|
|
03.14 |
Monoclonal Antibody
(4,0)
|
|
03.15 |
Cystic Fibrosis
(1,0)
|
